Core Viewpoint - Japan's antibiotic raw material supply chain is heavily reliant on imports from China, prompting local companies to invest in domestic production to achieve self-sufficiency by 2028 [1][2]. Group 1: Company Initiatives - Fujifilm Holdings will begin producing antibiotic raw materials by 2028, aiming to meet all domestic demand in Japan [1]. - Meiji Holdings plans to restart its raw material production equipment in the fall of 2025, marking a 30-year hiatus [1]. - Otsuka Holdings' subsidiary, Otsuka Chemical, will build a new factory in Tokushima Prefecture by 2030 to enhance the supply system for penicillin-type antibiotic raw materials [2]. Group 2: Investment and Production Plans - Fujifilm Toyama Chemical will invest approximately 10 billion yen to expand its factory in Toyama City, focusing on the mass production of ampicillin hydrate, a key raw material for penicillin-type antibiotics [1]. - The entire antibiotic raw material supply chain is being constructed domestically, with support from the Japanese government through subsidies [1][2]. - Meiji Seika Pharma, a subsidiary of Meiji Holdings, will produce raw materials at its factory in Gifu Prefecture [2].